MedPageToday -- SAN ANTONIO -- The injectable anti-bone metastasis drug denosumab (Xgeva) delays skeletal complications of breast cancer five months longer than zoledronic acid (Zometa), an intravenous bisphosphonate considered the standard of care, researchers reported here.
